Tags

Type your tag names separated by a space and hit enter

Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia.
Diagn Microbiol Infect Dis 2005; 52(2):113-22DM

Abstract

We performed a retrospective cohort study to determine the morbidity, mortality, and hospital costs attributable to methicillin resistance in patients with S. aureus bacteremia (SAB). Episodes of SAB occurring at the Detroit Receiving Hospital in 1999-2001 were evaluated. Controlling for confounding variables, patients with methicillin-resistant Staphylococcus aureus (MRSA) had a 1.5-fold longer length of stay (19.1 versus 14.2 days, P = 0.005) and a 2-fold increased cost of hospitalization (dollar 21577 versus dollar 11668, P = 0.001) compared with methicillin-susceptible S. aureus (MSSA). MRSA patients were at increased risk for delayed treatment, and delayed therapy was an independent predictor of mortality. Efforts should be made to ensure that appropriate therapy is initiated promptly in patients at risk for MRSA. Infection control policies must be strictly enforced to limit the spread of MRSA and potentially minimize excess hospital expenditures incurred with MRSA. With the advent of new treatment options, the impact of MRSA will need to be revisited to determine if these therapies can remedy the increased morbidity associated with MRSA.

Authors+Show Affiliations

Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA. lodiset@acp.eduNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15964499

Citation

Lodise, Thomas P., and Peggy S. McKinnon. "Clinical and Economic Impact of Methicillin Resistance in Patients With Staphylococcus Aureus Bacteremia." Diagnostic Microbiology and Infectious Disease, vol. 52, no. 2, 2005, pp. 113-22.
Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2005;52(2):113-22.
Lodise, T. P., & McKinnon, P. S. (2005). Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagnostic Microbiology and Infectious Disease, 52(2), pp. 113-22.
Lodise TP, McKinnon PS. Clinical and Economic Impact of Methicillin Resistance in Patients With Staphylococcus Aureus Bacteremia. Diagn Microbiol Infect Dis. 2005;52(2):113-22. PubMed PMID: 15964499.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. AU - Lodise,Thomas P, AU - McKinnon,Peggy S, PY - 2004/09/02/received PY - 2005/02/02/accepted PY - 2005/6/21/pubmed PY - 2005/9/16/medline PY - 2005/6/21/entrez SP - 113 EP - 22 JF - Diagnostic microbiology and infectious disease JO - Diagn. Microbiol. Infect. Dis. VL - 52 IS - 2 N2 - We performed a retrospective cohort study to determine the morbidity, mortality, and hospital costs attributable to methicillin resistance in patients with S. aureus bacteremia (SAB). Episodes of SAB occurring at the Detroit Receiving Hospital in 1999-2001 were evaluated. Controlling for confounding variables, patients with methicillin-resistant Staphylococcus aureus (MRSA) had a 1.5-fold longer length of stay (19.1 versus 14.2 days, P = 0.005) and a 2-fold increased cost of hospitalization (dollar 21577 versus dollar 11668, P = 0.001) compared with methicillin-susceptible S. aureus (MSSA). MRSA patients were at increased risk for delayed treatment, and delayed therapy was an independent predictor of mortality. Efforts should be made to ensure that appropriate therapy is initiated promptly in patients at risk for MRSA. Infection control policies must be strictly enforced to limit the spread of MRSA and potentially minimize excess hospital expenditures incurred with MRSA. With the advent of new treatment options, the impact of MRSA will need to be revisited to determine if these therapies can remedy the increased morbidity associated with MRSA. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/15964499/Clinical_and_economic_impact_of_methicillin_resistance_in_patients_with_Staphylococcus_aureus_bacteremia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(05)00036-2 DB - PRIME DP - Unbound Medicine ER -